Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Combining axicabtagene ciloleucel (axi-cel) or relmacabtagene autoleucel (relma-cel) with HDT/ASCT in relapsed/refractory large B-cell lymphoma: A single-center experience

Wei LIU, Yan Xu, Yi Wang, Weiwei Sui, Wenyang Huang, Lugui Qiu, Dehui Zou

Blood (2025) 146 (Supplement 1): 3720.

https://doi.org/10.1182/blood-2025-3720

Published: 2025

Journal Articles

A prospective, single-center, single-arm clinical trial of zanubrutinib monotherapy and zfcg combined therapy was given sequentially for the treatment of primary symptomatic CLL/SLL (Stop Trial)

Tingyu Wang, Yuting Yan, Ying Yu, Xiong Wenjie, Rui Lv, Tengteng Yu, Wei LIU, Yan Xu, Weiwei Sui, Wenyang Huang, Shuaishuai Zhang, Qi Wang, Lugui Qiu, Shuhua Yi

Blood (2025) 146 (Supplement 1): 2124.

https://doi.org/10.1182/blood-2025-2124

Published: 2025

Journal Articles

Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: The first real-world data from a single Chinese center

Blood (2025) 146 (Supplement 1): 4074.

https://doi.org/10.1182/blood-2025-4074

Published: 2025

Journal Articles

CART–ASCT–CART2 sandwich regimen as frontline therapy: A phase II trial in patients with primary plasma cell leukemia

Jingyu Xu, Qirui Bai, Yuntong Liu, Wenqiang Yan, Shuaishuai Zhang, Wenyang Huang, Chenxing Du, Lugui Qiu, Gang An

Blood (2025) 146 (Supplement 1): 4067.

https://doi.org/10.1182/blood-2025-4067

Published: 2025

Journal Articles

Safety and effectiveness of brentuximab vedotin in Chinese adult patients with classical Hodgkin's lymphoma: Results from a multicenter, prospective, observational, real-world study

Wei Li, Chuanxu Liu, Wenyang Huang, Ou Bai, Lihong Liu, Zengjun Li, Wei Xu, Wei Zhang, Liping Su, Kaiyang Ding, Luqun Wang, Guohui Cui, Hongmei Jing, Jianli Wang, Ziheng Guo, Weili Zhao, Huilai Zhang

Blood (2025) 146 (Supplement 1): 7135.

https://doi.org/10.1182/blood-2025-7135

Published: 2025

Journal Articles

Pola-R-edch shows high response rates in high-risk aggressive B-cell lymphomas or PMBCL: A phase 2 study

Wei LIU, Yi Wang, Huimin Liu, Qi Wang, Hesong Zou, Yan Xu, Wenyang Huang, Lugui Qiu, Dehui Zou

Blood (2025) 146 (Supplement 1): 3683.

https://doi.org/10.1182/blood-2025-3683

Published: 2025

Journal Articles

Safety and effectiveness of brentuximab vedotin in patients with CD30- positive B-cell lymphoma: A multicenter, prospective, observational, real-world BRAVE study in China

Jia Li, Wei Zhang, Huaqing Wang, Weili Zhao, Chuanxu Liu, Kaiyang Ding, Wenyang Huang, Zengjun Li, Xiaobo Wang, Hongmei Jing, Zheng Ge, Jianli Wang, Ziheng Guo, Huilai Zhang, Ou Bai

Blood (2025) 146 (Supplement 1): 5466.

https://doi.org/10.1182/blood-2025-5466

Published: 2025

Journal Articles

Promising safety and efficacy of equecabtagene autoleucel (eque-cel) followed ASCT in ultra high-risk multiple Myeloma (UHR-MM) patients: primary real world data from a single center

Blood (2025) 146 (Supplement 1): 2299.

https://doi.org/10.1182/blood-2025-2299

Published: 2025

Journal Articles

Chidamide in combination with azacitidine, mitoxantrone liposomes, and prednisone (CAMP regimen) for treatment-naïve TFH-derived peripheral T-cell lymphoma

Huimin Liu, Wei LIU, Wenyang Huang, Yi Wang, Lugui Qiu, Dehui Zou

Blood (2025) 146 (Supplement 1): 1864.

https://doi.org/10.1182/blood-2025-1864

Published: 2025

Journal Articles

Clinical characteristics and prognostic analysis of 52 cases of ALK-positive anaplastic large cell lymphoma

Wen Zhang, Wei LIU, Ting Xie, Tingyu Wang, Xiong Wenjie, Hesong Zou, Yi Wang, Shuhua Yi, Wenyang Huang, Lugui Qiu, Dehui Zou

Blood (2025) 146 (Supplement 1): 7165.

https://doi.org/10.1182/blood-2025-7165

Published: 2025

Journal Articles

Serum free light chain escape before IMWG progression: A predictive marker and a therapeutic opportunity

Blood (2025) 146 (Supplement 1): 4015.

https://doi.org/10.1182/blood-2025-4015

Published: 2025

Journal Articles

Determination of MYD88 and CXCR4 Mutation for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Blood (2024) 144 (Supplement 1): 4349.

https://doi.org/10.1182/blood-2024-202324

Published: 2024

Journal Articles

Γδ and Αβ T-Cell Large Granular Lymphocytic Leukemia Have Similar Characteristics and Outcomes

Blood (2024) 144 (Supplement 1): 1678.

https://doi.org/10.1182/blood-2024-202457

Published: 2024

Journal Articles

Response-Driven Dose-Intensified Immunochemotherapy ± Autologous Stem Cell Transplantation in Previously Untreated Patients with High-Risk Aggressive B-Cell Lymphoma: Results of the DLCL002 Phase 2 Trial

Ting Xie, Wei Liu, Wenyang Huang, Huimin Liu, Weiwei Sui, Yi Wang, Wenjie Xiong, Yan Xu, Lugui Qiu, Dehui Zou

Blood (2024) 144 (Supplement 1): 4481.

https://doi.org/10.1182/blood-2024-204363

Published: 2024

Journal Articles

Zanubrutinib Plus Ixazomib & Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia:a Phase II Studyshort Title: Zid for Waldenström Macroglobulinemia

Xiong Wenjie, Yuting Yan, Tingyu Wang, Weiwei Sui, Ying Yu, Tengteng Yu, Rui Lyu, Wei Liu, Huimin Liu, Gang An, Wenyang Huang, Dehui Zou, Lu-Gui Qiu, Shuhua Yi

Blood (2024) 144 (Supplement 1): 1648.

https://doi.org/10.1182/blood-2024-198864

Published: 2024

Journal Articles

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients

Blood (2024) 144 (Supplement 1): 7236.

https://doi.org/10.1182/blood-2024-197883

Published: 2024

Journal Articles

Phase II Clinical Study of Zanubrutinib Combined with Bendamustine and Rituximab (ZBR) for Time-Limited Treatment of Waldenstrom Macroglobulinemia

Xiong Wenjie, Yuting Yan, Ying Yu, Tingyu Wang, Wei Liu, Gang An, Weiwei Sui, Wenyang Huang, Dehui Zou, Lu-Gui Qiu, Shuhua Yi

Blood (2024) 144 (Supplement 1): 6324.

https://doi.org/10.1182/blood-2024-198882

Published: 2024

Journal Articles

Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression

Blood (2024) 144 (Supplement 1): 4439.

https://doi.org/10.1182/blood-2024-201476

Published: 2024

Journal Articles

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients Who Failed or Had Suboptimal Response to Standard First Line Triplet Based Therapy

Blood (2023) 142 (Supplement 1): 6864.

https://doi.org/10.1182/blood-2023-184868

Published: 2023

Journal Articles

Static and Dynamic Assessment to Identify Ultra-High Risk Multiple Myeloma：Analysis for Patients with Overall Survival No More Than Three Years

Yan Xu, Gang An, Shuhui Deng, Weiwei Sui, Wei Liu, Wenyang Huang, Tingyu Wang, Shuhua Yi, Dehui Zou, Lugui Qiu

Blood (2023) 142 (Supplement 1): 6701.

https://doi.org/10.1182/blood-2023-189353

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Combining axicabtagene ciloleucel (axi-cel) or relmacabtagene autoleucel (relma-cel) with HDT/ASCT in relapsed/refractory large B-cell lymphoma: A single-center experience

A prospective, single-center, single-arm clinical trial of zanubrutinib monotherapy and zfcg combined therapy was given sequentially for the treatment of primary symptomatic CLL/SLL (Stop Trial)

Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: The first real-world data from a single Chinese center

CART–ASCT–CART2 sandwich regimen as frontline therapy: A phase II trial in patients with primary plasma cell leukemia

Safety and effectiveness of brentuximab vedotin in Chinese adult patients with classical Hodgkin's lymphoma: Results from a multicenter, prospective, observational, real-world study

Pola-R-edch shows high response rates in high-risk aggressive B-cell lymphomas or PMBCL: A phase 2 study

Safety and effectiveness of brentuximab vedotin in patients with CD30- positive B-cell lymphoma: A multicenter, prospective, observational, real-world BRAVE study in China

Promising safety and efficacy of equecabtagene autoleucel (eque-cel) followed ASCT in ultra high-risk multiple Myeloma (UHR-MM) patients: primary real world data from a single center

Chidamide in combination with azacitidine, mitoxantrone liposomes, and prednisone (CAMP regimen) for treatment-naïve TFH-derived peripheral T-cell lymphoma

Clinical characteristics and prognostic analysis of 52 cases of ALK-positive anaplastic large cell lymphoma

Serum free light chain escape before IMWG progression: A predictive marker and a therapeutic opportunity

Determination of MYD88 and CXCR4 Mutation for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Γδ and Αβ T-Cell Large Granular Lymphocytic Leukemia Have Similar Characteristics and Outcomes

Response-Driven Dose-Intensified Immunochemotherapy ± Autologous Stem Cell Transplantation in Previously Untreated Patients with High-Risk Aggressive B-Cell Lymphoma: Results of the DLCL002 Phase 2 Trial

Zanubrutinib Plus Ixazomib & Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia:a Phase II Studyshort Title: Zid for Waldenström Macroglobulinemia

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients

Phase II Clinical Study of Zanubrutinib Combined with Bendamustine and Rituximab (ZBR) for Time-Limited Treatment of Waldenstrom Macroglobulinemia

Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients Who Failed or Had Suboptimal Response to Standard First Line Triplet Based Therapy

Static and Dynamic Assessment to Identify Ultra-High Risk Multiple Myeloma：Analysis for Patients with Overall Survival No More Than Three Years

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only